BCRX - Earnings call transcript Q1 2018 | BioCryst Pharmaceuticals, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, ladies and gentlemen. And welcome to the BioCryst First Quarter 2018 Earnings Conference Call. At this time, all participants are in a listen only mode. Later, we will conduct the question-and-answer session and instructions will be given at that time. [Operator Instructions] As a reminder, this call is being recorded. to Officer. conference like Staab, to now Financial Chief would turn over the Tom I begin. Please

Tom Staab

you, Thank conference Dr. Officer morning, on me corporate Officer. release Good today Latoya. Medical accompanying Bill our update quarter BioCryst's and Stonehouse, the and Sheridan, XXXX website. first are Participating Chief financial call are Jon and results slides call. on press and Today's available welcome with to Executive Chief

our Following remarks, answer we questions. your formal will

to investment I Slide of begin, to want our potential your attention which we use X, Before forward-looking risk direct discusses factors in and statements regarding an BioCryst.

on to performance and different performance regarding in be call will or to may and future and/or uncertainties, achievements. detailed the information, contain or results, or statements subject and slide, unaudited materially as those this financial actual These forward-looking known statements including risks As results which today's expressed results, performance, future as the unknown our cause future achievements presentation. forward-looking implied standalone from conference well any statements, are company's

place You forward-looking statements. on these not undue reliance should

including on a would like information and documents Jon. to to Commission, risk the Securities of be with discussion to I the additional For company's factors, please filed can which over call Exchange our the our website. accessed refer detailed turn now

Jon Stonehouse

medicine up strategy program of a oral a our the which start and enrolling in BCXXXXX, indicator once for planned a XXXX, announcing trial implementing has the in Thank first treatment. HAE. program, a capsule for you, advancing testing or for sites advanced and optimizing of now Tom, hereditary APeX-X day got the is programs, the of good screening rapidly the once is The morning, The and most and thanks strong good programs running patient. We up good off in that of U.S. APeX-X demand one our for joining a long-term are trial clinical late-stage angioedema prevention us this Most for day to our also pivotal today. and our is value. the plan, for attack

we coming In Europe screening the in held and weeks. in patients our expect be European at meeting sites addition, to recently investigator

on weeks track the this the safety first trail So and of results we from report first to efficacy of remain half next year. XX in

APeX-X strategy Our utilize of U.S. prophylactic pivotal only to for weeks completed. part enrollment first. XX this sites for is one the prioritize the program until first trial is And

is safety start-up component focused important now previous called enrolling. for in this the an next NDA APeX-S Europe initially Our has a to due trial label is and U.S. longer outside sites of trial up is the slower trial trial, open time. this Like XXXX the priority filing. data Enrollment also is EU ramp our for of Safety from APeX-S. and running

Our target the in of remains second for XXXX filing half on track.

is to Zenith-X, formulation are also an we acute prophylactic, acute over patients enrollment also for ramping X of with studying In XXXX of of addition oral for trials up advancing well. our of HAE Phase treatment attacks with XX% liquid is clinical XXXX Zenith-X enrolled. HAE treatment attack.

cohort the to the on XXX third year. on of report the to remain this now and enrolling are milligram dose. results milligrams We patients We at XXX the track dose quarter the cohort from third in

are BCXXXXX Progressiva studies. toxicology also FOP are Fibrodysplasia treatment programs early are or announced proceeding Both of ALKX the Inhibitors recently Ossificans for unscheduled. Our BCXXXXX and entering

next on as X trials molecule a is enter half BCXXXXX year. for track first We in the of toxicology clinical Phase addition, to entering remain disease each well. rare In these different of for studies programs

of that announced discovered a Top the complicated the value. our we dose acute creating of additional last Wrapping and up IV-infusion program way by of of sustainable the peramivir having treatment While and approval in-house EMA. these the refill for molecules programs is update, antiviral single important name to pipeline influenza Europe. brand our week new early in are is in

We dispute payment partner our also number those including of press a topics a incumbencies million contested that for noted with in of release Seqirus we're a our milestone in in $X Europe. approval

RAPIVAB we have the received U.S. of procurement notice Lastly, for pre-solicitation the the government the replenishment stockpile. additional for CDC by of

now of completed by over quarter Tom will first of to for have program to That's expect I it turn September. at We fiscal government's procurement through the who update; go the discussions the the financials. end end will the year it Tom?

Tom Staab

to My BioCryst our Thanks pending our not results. impact relates first XXXX a reporting through the expenses far. importantly September and to Jon. in and the and Idera million APeX-X merger. on cash comments that statement discuss reflect approximately company XXXX quarter financial us liquidity BioCryst pleased clinical standalone from BioCryst focused proposed thus reported exception capital course do The of been quarter beyond of details incurred is the closed expected of of I'm is the combination trial merger are provide to results. have $XXX the the to a and for We with Zenith-X This investments.

pleased in thankful far and thus with study progress that our we beyond runway very have data points. cat are important We the these extending a are

Canadian well we derived government from on expect a stockpile. recur to approval payment quarterly Japanese decreased were that normally decrease XXXX revenue XXXX. million from is $X of events infrequent, $X.X not recur primarily $X.X our first XXXX. the Those The first and million basis somewhat the derived as million that Turning was to royalties to milestone events quarter as of in in to not did $X due $X.X million a XXXX million are Slide to XX, events recorded revenue of quarter for do of related from RAPIVAB

the do we While due these of transactions the and and to difficult processes. appropriation relevant government the stockpile amount expect its to to and other timing governments is because profile, Japanese unique product stockpiling government's RAPIVAB of predict

XXXX. of in The $XX.X our activity with XXXX increased from in resulted These personnel R&D from peramivir was first related $XX.X our $X.X on in expenses increased to million the as General levels million the and million result for $X.X pending spending increased on incurred support for of Zenith-X of increase decrease due all expenses [galadasivir] preclinical XXXX million to development the to the up quarter compared in compared by with to were that incurred increased merger costs the clinical and a programs. evolution administrative were of million well XXXX. as XXXX increase of quarter lower programs, Idera. quarter to merger trials XXXX $X.X in additions of First offset primarily largely of partially ongoing first first XXXX. surrounding R&D quarter The the of and APeX-X, as and as HAE associated APeX-S, expenses our

quarter the incurred the below incurred first expense in line, $X.X the line $X.X Moving quarter XXXX. of of in million the operating interest is million in XXXX with we of first which

mark-to-market hedge and a In first rate exchange losses agreement. of changes $X.X quarter from mark-to-market recognized $X.X quarter million the valuation of in we Yen the related addition, XXXX. loss loss as first These compared dollar, million underlying U.S. in the to in our of mark-to-market Japanese XXXX, result the periodic

no underlying in mentioned losses cash outflow. these quarters, As the have previous

first $X.XX share $XX.X Our million net quarter compared loss XXXX. loss XXXX or to the as of was first of per in in million or $XX.X quarter the $X.XX

our expenses impacted reliably guidance, million due approximately cash as million. of this the our to XXXX range of the our Moving a and quarters, are as to projecting the $XXX guided operating we compensation Consistent performance With on divesting of options. both costs XXXX operating to advancement outstanding aggressive to by $XX price million. XX, is the cash base our our of cash and end as March with $XX XXXX our for our in quarter million. in difficulty be merger utilization to trending the And was guidance to million balance stock to was upper of stock, range the at million programs, In well expense related volatility equity XX, and $XXX utilization $XX.X previous by expense regard Slide to continue expect $XX we and excludes in ranges. the the base of Company's currently a it first

back closing to to remarks. turn Now, call his over like I'd Jon, for the

Jon Stonehouse

I'd Tom. of a our announced you to conclude merger brief update proposed Idera. like by with Thank previously providing

merits We the spent have the transaction, company shareholders financial will on of several which to create last a new and strategic weeks [Valencia]. engaging with called be

will to excited and able mean, Idera's chemistry to compelling benefits oligonucleotide led stage the competitive of of small We about from one and complementary combining of capitalize both as rare very treatments more can both programs, molecule opportunities can disease expertise We commercialize goal diversifying targets and development. can the rare a small allowing discovery development. integrate of continue to value more will be within unique other to be combination us opportunities to patients of X This variety things, be potentially by will both create and Among supporting believe strategic on and of be rare synergistic number two product company the this employees a many targets development companies. robust acid effective organization. and many the stockholder its two programs chemistry enhance and with expand Company BioCryst to Phase diseases, have Together diseases, nucleic more pipeline ability behalf ultimately as molecule separate combined us disease on have that advanced engines short-time delivered growth programs be leverage guided, into the expand stage we oligo into early value. disease a rare more more rare the combination, that focused opportunities. late [Valencia] and on enhanced advanced may create structured design for and creation stockholder by giving and and development assets candidates that X talents successfully with the risk well number for Phase we'll and and

by deliver this with by small in Idera's the other pursues, potential the may that For oligonucleotide for organs establishing chemistry a combining more opportunity primarily growth creates and molecules exciting oligo's other are to to opportunities however, platform be in oligo's, We kidney we example, and target to the BioCryst words, success and differentiated. broader believe body. targets liver, unique able

to positioned making well increased financial research efforts. fund the Lastly, and launch discovery Company internal will development, combined commercial flexibility, clinical and strength it preparation have

of proposed the invite all is of us as at at approval by on We merger July to As on you XXXX, vote join to know XX, companies. the Eastern. record May meeting of to the XXXX AM subject XX:XX transaction XX, stockholders special stockholders both our

so towards patients employees, We to completing to combination the of can that work and benefits the transaction, the we continue stockholders. deliver

the as at looking Society on on Idera's June American about presented keep remain also Chicago as are program, our We new in continue and forward this financial prepared oncology combination will data clinical We you which on the it X. to of and clinical confident ever progress. IMO-XXXX be our the to updated remarks. benefits for will deliver That's we'll that strategic meeting

it will for up We your now questions. open

Operator

[Operator you. Instructions] Thank

Capital Abrahams from is Brian question of first The RBC Markets.

Your line open. is now

Brian Abrahams

my the terms as study, XXXX show on there, you GI on this HAE the and Hi be - observing the I XXXX, blinded can well high A in ramping maybe anything safety you're will there confidence dose? proposed the attack program the what there of about on that of merger. gives show the benefit a the as question taking say Zenith thanks tolerability enrollment for study with guess and clearly for couple rate with on to basis up. questions. in able that Is you then confidence starting on

Bill Sheridan

study Hi, of the Thanks blinded is for Bill. of as out. course Brian. the question. The this you Hi, is pointed oversight

treated a patient have that's a looked that's fixed investigator. that as operational care diary over and in so that's for site the And The in attack the for era going going hereditary the fill need to compliance telephone well. to and the just at investigator angioedema patient, events patients that's as study of acute the this need are of self-administered the reminder perspective. modern into treatment attacks done so And treatment the We home out well. both with experimental be qualified from

analyze and So view to drug is a point of that from to the need the of of gathering effective. whether come conclusion we data the

operational delivering the confident we what feel will that exactly pretty of need. the aspects think we study I

we haven't issues. well; any going that's site So had

Brian Abrahams

Great.

going we as in to be that versus proposed for of standpoint the Bill, that that potentially little synergies talk from as what looking forward merger, specifically And needs kind go the potential be you the in to to expecting part and and latest updates about a in through noted quantify a of merger terms costs. some degree? if you're On related due expenses Can as the end well higher the out, you should maybe BioCryst bit cash costs on of operating merger of to range company more were washing the those standalone? combined financial a

Tom Staab

Sure, Brian. It's Tom.

related in our of ranges, So to first of factors were the merge And under One our to that. been the costs in of $X.X pre-clinical contributed HAE all, of million, two expenses program also some aggressive $X the regards really up that operating there - the end million. but are upper advancement our just program. predominantly is

related and when what did as moving or our than quicker we anticipate budget. due merger didn't diligence in quick So that's anticipated we And as we budget costs. obviously our any

in you forecasted think runway both at end into In organizations organizations, three. speak can two and XXXX of upper I to of million obviously regards they in both so $XX I've pushes cash public recent they've counterpart through year synergies and million between the also heard but ranges. year expect the factors Idera, as have total mentioned those cash a the it our that September for in also BioCryst, reporting. I $XX And And my of of most two for

entity would procedures. still it the And would information. after come to some to take what combined public the the think some will closed sure like out time that I we're be because So was going with I'm discuss deal inappropriate through integration look

Jon Stonehouse

that's categorize my likely add substantial. talked more bit in flexibility the some will just company have, remarks the financial and about Brian, bit a the that I I in what Tom the that in prepared would new me term off comes short as of stuff stuff that let some So of that further more and form and a then

in opportunity because contract on got combined procurement Idera cap there that We with There ability they've this that likely in that warrants mid to we're opportunity the side, we to additional more to have bringing back. assuming So would is the additional they've of pay bucket the that that from brought sale of gotten of is in capital. company refinance the runway that the capital.

things on in million together all to of And range so additional really that where bigger roughly. then of we're Idera number confident take the be And something million could there is is that bringing strength refinancing And in of then player. requires term a that able it relatively $XX what of to be talked able advantage we'll working do. that a is we've longer couple that $XX about other somewhere that financial capital before different it's clear types the is to really using that to much XXXX that tumor

we milestones the level could talked deal think then heading with confident finalize month payment from in And an the an to the for license about XXXX And interest Bill so of we start conversations there this strategic that shortly we've after partners remain a we'll is And Japan and helping that hopefully upfront will the future ability Japan. to working bring also be and be company. fund in be both Japan. PMDA. out-license to substantial in development the there And our And with in plan that players space. could could that be

the they funding bigger chunks clinical make research. of and are can in things programs funding those think of So a launch the that really difference other advance funding we development XXXX, as

Brian Abrahams

That's thanks Tom. really and helpful, Jon

out guess that I'll consideration should you, looking things are guess guess in of synergies I if misspoke data key the question that Bill coming I influence that And what more one ASCO I the but at of be merits, scientific meant and rationale potential might have of what for XXXX may. I the risk the the hop for Sorry I do the queue. Thanks. the I we I profile for question back merger? the

Bill Sheridan

My be melanoma. XXXX response And an update of ongoing their Phase X ipilimumab Sure. experiment of that an understanding is the rate. in they had plus there'll impressive

items. the durability the So responses an on key and the of rate response the update

I And think on interesting combination profile that is study be to that similar we that psyche of satisfied our psyche of to pretty progress going profile the is alone. really to the were review the see. ipilimumab

would it that double market in time inhibitor oncology think already the very is we the which lot about they their the original presentation. you which that we asset initially say a clear of I have research XX% in response who lower alone impressive. at our that taking we independently failed diligence people the rate into account very response [Indiscernible] value rate checkpoint is the saw took would response was feedback overall to did get community in with rate the of than be And

see things they think are I be will looking we an forward on. the main So update to

Jon Stonehouse

to you dataset that that is seeing what more larger yes real. patients you're And go XX much gives from XX confidence you patients, so

So coming on that out Xth. June forward data we're looking to

Operator

Liisa The Bayko of is next you. Thank from JMP Securities. question

is line Your open.

Liisa Bayko

Phase kind Hi, the getting going congratulations merger on of and the to forward design looking up completing. X and

about terms actually for patients targeting background this what-? Phase question Phase sort know what rate of to X be of the you you kind for a Just of going in of X the are

Bill Sheridan

question. thanks for Again the Liisa. hi, Yes,

criteria the able on So APeX-X. longer a to liberalize lot than We've tech study the is the because been right. eligibility

of out respect taking and with people So to of comply good one trial, around to able is clinically that month so. have clinical are criteria to otherwise studies. the to medication, about actually filling typical eligibility visits all health or an running oral requirements diaries, in study In the other be the be study important

the circumstances, a to adult at that's of able I angioedema described. and a general broad sort do lessen those but hereditary with in patient U.S. in at every various not in population So things

Jon Stonehouse

his previous has a to and team we've run. that would Bill lot learned trials I add that from

that their we're so condition. one out screening and don't understand and we And people And HAE just the process overall qualify that sure knocking that making number these know people and do. that keeping have people

getting We even we're getting at study. Phase X when we're at better a that. in before think were it think much that's good I I but better critical and you're

Liisa Bayko

that the some medication does you terms will work? other wash-up how here, have prophylactic that been of And of on patients in have

Bill Sheridan

reasons influence. --the it's for We care we other Also their study. the reasons. obvious think with don't their for medicines medical patient try I and choices prophylactic of obvious Sure and about targeted for can't during to on We medicines attack given physician. influence in acute can't We HAE to all medicine treatment. treat or one have individual we don't the that specifically have are and our to insist continue acute of studies acute will availability modern allow the attacks of other

So there range therapies experience will prior with we that and in be of diversity studies. our a other see whole

prophylactic We the therapies expect experience of many gain that here market. to see people already had the with are who the with on

Jon Stonehouse

She had a about question washout.

Bill Sheridan

on determined half-life washout the Yes, is drug. the the of based

on So for example, if take to a washout. people have before antigens that while been

there during adequate can't, they each period into well. part for is randomized there study. element the screening washout prospective the occasions. come designed the process the screening don't I an straight a of of prophylactic is So And to here as

can't screening prophylaxis So during any the portion prospective either. beyond they

Liisa Bayko

your and in so you so on kind terms and helpful makes of that's us prevalent Okay, sense. here forth? terms give assumptions timing the and run of like from of Can through

Bill Sheridan

Sure.

guidance on that. changed haven't I think their we

to into next [indiscernible] combined read and out our of recruit will the There in the So maturing our also to safety also an account those how will will it that recruit program, run are middle is estimates best run study. APeX-S long long of important. takes it of study year. And take both take because planning and how

lead second an combined So all before said Jon the year. in next those to things half NDA of of timeline as

the from year. XX will the the of that next we read analysis and of week of point think anticipate efficacy get when middle safety APeX-X, I a we view for out of before

Operator

Maury with from next Jefferies. Thank you. The Raycroft is question

open. line Your is

Maury Raycroft

into the the heterogeneity general study? patients? the about have can patients and on in If talk can history morning on attack perspective coming between To screening the if rates Zenith, progress. congrats on how and start the good any Hi, you much provide baseline for you baseline you

Bill Sheridan

Interesting question, thanks Maury.

kind have Zenith, what with a back not attack. a, an I and it's Prophylaxis think Kallikrein our our doing to normal for special seeing we're it's once b, inhibitor oral need recovery of accelerate with very intervention is the study you because,

visual of So like attack measuring the scales, the severity during resolved. sorts the symptoms I and quickly they're the things things and how analog

oral of clearly For that for you type an then oral the if and medicine treat study, and an attack if can't you're medicine example. is swallow swallow you going to attack vomiting the important to

liberal go on attack as heterogeneity So of mentioned get for through qualified. historical It's pretty in is will taking range of of X to time has a I frequency. attack qualified before, total be people each There attacks study. terms It a whole to again.

just example, and get reason you to is want it. to a that's the the that's not time physicians report know For o'clock don't - experimental they commonest and attack treated that not with probably morning do in file particular an X and if suitable the it's physician the why call medicine,

into So Jon before. estimates that's the factored mentioned the

able and in We confident having the of I through then taking third through three and site it's taking But we'll to and time. a it people that's all working; one a attacks operationally take process quarter. go investigator mentioned at the the just of medicine. result are to does time the top to calling report very be And as get qualified some

Maury Raycroft

will And top-line or data be that the expect press XQ the a Zenith, conference? helpful. we very at Okay, in that update release for medical for should

Bill Sheridan

it of You that in line very we've the company had announcement and studies. of a that amount done out fair a detail, time results each should top on important that in coming in we've expect past

Maury Raycroft

okay. all and should results for do is specified the disclose safety you'll you study, when or you the could And the if you for EMA, study those safety FDA analysis it, from then disclose, Got analysis? when

Bill Sheridan

we continue accumulate treated and which studies, the duration the we entire label safety no with data way by of drug safety get of patients and that study NDA so involve. in Each active data on there we'll put to to NDA. continue a the commercially timeline So, an the study, until the the the XX safety subject cut seeing NDA. firm the studies after is open is filed available for safety we'll the And keep agents blinding it's submission. we a safety days is do and data. that we'll days, then to additional And there analysis for The once the is XX the after the timing efficacy up update, of traditionally NDA submission

So stated about there the are business. is nothing just that in of doing way particular regulations guided that that

Operator

Thank Needham the Belanger Company. you. question The Serge next is from of and

Your is open. line

Serge Belanger

morning. good most on initial U.S., Hi, the - recruit the Couple take in you place recruitment questions of XXXX, APeX-X will while will the EU. that from talked APeX-S will

of makeup and Just do you enrollment and numbers expect between thoughts wanted of kind that EU what in the your on APeX-X the final strategy study? U.S. patients, the

Jon Stonehouse

Yes.

said So, of terms is priority. let Serge, we me Jon, on just what this in clarify

additional weeks, into patients the be XX XX for will to U.S. study. will over and half well. course enrolled, first the the rolling APeX-X the as the we've first And be so completed. weeks, U.S. said open completed that in safety of once that qualifies APeX-S used sites that the will until fully the Then up second is those patients which we've getting what is only of is for we priority data So, for

starting of are as We APeX-S a that. result

because out nicely APeX-X. works patients in can't are or reuse and from We that Europe APeX-X either Zenith we in starting APeX-S

over APeX-S. but enroll an can so we an And

also addition coming XX enrollments currently. expand beyond Europe. the And from that coming where over when we quarters we'll first largely the that's U.S. regions to expand other completed, So weeks is in then will the

Bill Sheridan

that and representation patient to for will the for you and if have regions. thoughtful both marketing Serge, U.S. both our studies anticipation Europe, are applications the

Serge Belanger

Okay. XXX Thanks report the in half you the Zenith-X expect of XXXX? On the for second clarification. mg cohorts

Bill Sheridan

we of that upgraded quarter to actually X-K. the third No,

Serge Belanger

your cohorts cohort numbers the So report cadence timing? what and smaller you other to a two terms of in of that do given with for additional experience think cohorts the the

Bill Sheridan

study analysis when will just the year. is that and to file Our next is plan a be finished

Jon Stonehouse

all Okay. like to said, then XXX patients We're - in three randomizing far and in with XXX analysis XX will along I milligrams attacks, we're a part attacks cohort be going first dose, of moving takes so we at the four milligrams tricky are months. part-by-part, good final do the and it a The And our is enrolled, cohorts. the already it XX% cohort we're the that for going have three are about have things thus is that a last patients only to experience so to following you three pace.

Bill Sheridan

average. On

Jon Stonehouse

average, On yes.

Bill Sheridan

you this So that if last - of about the study year. middle was when started remember

year. that report results So we'll the very study confident I think final next

Serge Belanger

order U.S. And one last I And XXXX question the you guess on just quick RAPIVAB, was I I or government stockpiling you give government XXXX? approval. this in history do recent can history of an of EU think expect any stockpiling a from us with RAPIVAB think there

Jon Stonehouse

Yes.

that. take me let So

So With I stockpiling, stockpiling. I in me approval, Those think so basically procurement in for XXXX think it's regard November-ish expire stockpile. for the replenish don't will to hard million. to we predict the courses and out. to purchased there's were we'll year anything currently but plays government five next timeframe $XX.X at hurts has so sold day which have that why But that to process see how to pre-solicitation begun U.S. XX,XXX European it with Europe, regard European is to that's the in you're correct, around

Operator

will Gena Thank be you. next Wang of The Barclays. question

Your line is open.

Gena Wang

taking for you my question. Thank

my I already being the of most think answered. questions

safety you from will just this data Just collecting any wondering attack APeX-S, quick, trial? the

Bill Sheridan

we'll pattern attack see attacks study. experiences prior the the absolutely will an Yes, of relate collect efficacy will study. during monitor question. It's of that and for interest the Thanks we not to data study, that to during patients be but it

Jon Stonehouse

Yes.

we information, then protocol I patients Gena will arm is is to way forward to XXX. that, think dose, be at XXX and are patients the the of milligram design, the one we put and appointment initially enrolling the randomize in important piece the with or other

Gena Wang

I see.

So that data point then with and how at investors? the data you do collecting what will you frequent share attack

Bill Sheridan

we'll analyze is for time this to So compiling mentioned stock the analysis before the is study plan when it's what NDA. I

using the diary. So a patient there - is data the way is collected is a

So NDA. clear ApeX-X. during know need we'll timing the compile study to that efficacy We'll when and from is will accumulate the analysis week that on the how got analyze XX it's the we that after

Jon Stonehouse

the there of the part don't report as pivotal Yes. Because once done part We the a the that want so jump cut filing. on anything data a says, of gun program we to and we'll have Bill and submitted. is

Gena Wang

regarding one Zenith-X. question and Okay then

your a in as expect So the the data top we'll successful will line half outcome? what definition second be this year,

Bill Sheridan

they because hours reported. so difference a worthwhile of exercise. of they a That's a XX%. And - go away. were active to the example. treat a and they maximum treatment XX% attacks you at generally very how range and to angioedema, forget results don't that is really people there between for The in And overtime, treatments the interesting every studies then spontaneously study look and reach if generally is here it's hereditary response attack there of the been four placebo the placebo of has It's acute question and designed placebo indeed at prior

going be know what basis predict able on what this question don't I be response high. the figure we'll we'll information call So see can on we'll is to the going of to see. I quality I to prior very the out of predict don't what's that the want the to because on because

when won't benefit before, clinical you attack rule talk looking you medicine. would be that be medicine have here can a think avoid is going than that they are they when you like from acute I vomiting There to an if And oral big out. patients. to an are some we're attacks for themselves said be important. that injecting I if that can oral That's deal So for what suitable

attack If with you're off you're having a those swallow, can't much rapidly progressive laryngeal you injection when circumstances. better an under

in in I So talked having attack in breathing or majorities not choice. with an acute give vast or treatment not most peripheral impaired think are The throat. about. with associated an categories patients that not or associated for oral impaired the the vomiting will swallowing I just constriction that or in attacks And

attacks be you for that the it if could big a of So would with example there simple treat are - a the deal. oral majority liquid

I that about see placebo effect. here the a be to think like from about clearly treatment whether criterion. We'd collaboration in with that's don't I advocates judgment to our benefit. patient We'd bottom a see make think And should that advisors different important. we to the success with pre-specified it there's able a like and line the So expert is it's

Jon Stonehouse

And oral about to with I talked it's XX% Bill that to an XX% think close treatment. that if

sometimes a think breakthrough because there's patients I we we attack. a burns the is injectable advantage hear what and have real from

an advantage treat a having I big that even a So attacks. lasts time is think if long oral really all we can't

Operator

back to Thank you. questions at this Stonehouse Jon over for further I'll no time. call turn the remarks. There are closing

Jon Stonehouse

patients makes here are So as The in advancing company. continue interest sense main forward push believe the The moving and always to Idera our shareholders, we merger messages as time. are And for with appreciate we the your are trains employees. programs as on that planned. we

have a great thanks interest and So day. for your

Operator

Thank concludes you. conference. gentlemen, this and today's Ladies

You may day Good not everyone. disconnect.

BioCryst Pharmaceuticals (BCRX) 8 May 182018 Q1 Earnings call transcript